Across the recent three months, 7 analysts have shared their insights on Moderna (NASDAQ:MRNA), expressing a variety of opinions spanning from bullish to bearish.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $123.43, a high estimate of $231.00, and a low estimate of $69.00. Highlighting a 21.76% decrease, the current average has fallen from the previous average price target of $157.75.

Investigating Analyst Ratings: An Elaborate Study

An in-depth analysis of recent analyst...